Zacks Investment Research·1 day ago
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.
Alnylam Pharmaceuticals, Inc.(ALNY)Earnings, Financials & Key Ratios
ALNY•NASDAQ
$321.59
138.0× P/E·Price updated Jul 7, 2026
AboutAlnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$3.71B+65.2%
- EBITDA$557M+563.5%
- Net Income$314M+212.8%
- EPS (Diluted)2.33+206.9%
- Gross Margin81.77%-4.5%
- EBITDA Margin15%+380.6%
- Operating Margin13.51%+271.7%
- Net Margin8.45%+168.3%
- ROE73.28%+117.7%
ALNY Price & Volume
Alnylam Pharmaceuticals, Inc. (ALNY) stock price & volume — 10-year historical chart
Loading chart...
Commercial Scaling Drives Positive Equity Inflection Point
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Improving
Primary Risk:Regulatory pricing negotiation exposure
Key Thesis Takeaways
- Alnylam has successfully transitioned into a commercial-stage powerhouse, evidenced by 96.4% year-over-year revenue growth in 2026Q1 and a shift to positive equity of $1.1 billion.
- While the company is achieving operating leverage with a 23.0% operating margin, investors should monitor the persistent disconnect between GAAP profits and cash generation, as evidenced by a 0.34 operating cash flow to net income ratio.
- Long-term success remains contingent on managing the $1.3 billion debt load and mitigating the impact of $70.2 million in quarterly stock-based compensation on shareholder dilution.
Verdict Logic
while the company has achieved a positive equity position of $1.1 billion, the current P/E ratio of 125.05 and the $281.7 million drag from working capital suggest that the market may be overestimating near-term cash conversion efficiency.
ALNY Growth Metrics
Alnylam Pharmaceuticals, Inc. (ALNY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years56.89%
5 Years49.77%
3 Years52.98%
TTM82.57%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM314.02%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM301.44%
Return on Capital
10 Years-25.97%
5 Years-10.53%
3 Years-0.23%
Last Year15.31%
ALNY Recent Earnings
Alnylam Pharmaceuticals, Inc. (ALNY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$1.51+73.2%
$0.87
Rev
$1.2B+4.6%
$1.1B
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.82-29.3%
$1.16
Rev
$1.1B-4.5%
$1.1B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$2.90+416.9%
$0.56
Rev
$1.2B+30.2%
$959M
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.32+158.9%
$0.54
Rev
$774M+16.7%
$663M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $1.51vs $0.87+73.2% | $1.2Bvs $1.1B+4.6% |
| Q1 2026 | Feb 12, 2026 | $0.82vs $1.16-29.3% | $1.1Bvs $1.1B-4.5% |
| Q4 2025 | Oct 30, 2025 | $2.90vs $0.56+416.9% | $1.2Bvs $959M+30.2% |
| Q3 2025 | Jul 31, 2025 | $0.32vs $0.54+158.9% | $774Mvs $663M+16.7% |
Based on last 12 quarters of dataView full earnings history →
Latest ALNY News
Recent stock market news and headlines for Alnylam Pharmaceuticals, Inc. (ALNY)
The Motley Fool·5 days ago
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.The company has six marketed therapies and several others in late-stage clinical trials. Alnylam has a unique drug delivery system that gives it a deeper moat.
Seeking Alpha·Jun 25, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders TranscriptAlnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript
Business Wire·Jun 25, 2026
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence PlatformNEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo's analytics AI platform, across key enterprise functions at Alnylam. Built on the Healthcare Map®, the industry's most comprehensive view of more than 330 million de-identified patient journeys, Marmot helps organizations move beyon.
Zacks Investment Research·Jun 22, 2026
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.
Peers Comparison
Key metrics vs top competitors for Alnylam Pharmaceuticals, Inc. (ALNY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $321.59 | $42.91B | 138.02 | 65.19% | 8.45% | 73.28% | — | |
| $86.33 | $14.27B | -36.27 | 33.87% | -30.87% | -58.57% | — | |
| $86.97 | $12.25B | -7128.69 | 23258.15% | -48.38% | -55.09% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $79.77 | $31.64B | -10.99 | -39.23% | -143.55% | -36.73% | — |
Compare ALNY vs Peers
Alnylam Pharmaceuticals, Inc. (ALNY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALNY SEC Filings & Documents
Alnylam Pharmaceuticals, Inc. (ALNY) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Mar 4, 2026·SEC
Material company update
Feb 12, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when ALNY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ALNY Frequently Asked Questions
Alnylam Pharmaceuticals, Inc. (ALNY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Alnylam Pharmaceuticals, Inc.'s revenue?
Alnylam Pharmaceuticals, Inc. (ALNY) reported $4.29B in revenue for fiscal year 2025.
How fast is Alnylam Pharmaceuticals, Inc. growing?
Alnylam Pharmaceuticals, Inc. (ALNY) grew revenue by 65.2% over the past year. This is strong growth.
Is ALNY profitable?
Yes, Alnylam Pharmaceuticals, Inc. (ALNY) is profitable, generating $577.2M in net income for fiscal year 2025 (8.4% net margin).
Dividend & Returns
What is ALNY's return on equity?
Alnylam Pharmaceuticals, Inc. (ALNY) has a return on equity (ROE) of 73.3%. This is excellent, indicating efficient use of shareholder capital.
What is Alnylam Pharmaceuticals, Inc.'s free cash flow?
Alnylam Pharmaceuticals, Inc. (ALNY) generated $641.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.